Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Bolt Biotherapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- +6 vs. Q3 2024
- Shares held
- 18.7M
- −127.2K (−0.7%) vs. Q3 2024
- Total value
- $9.99M
- −$2.18M (−17.9%) vs. Q3 2024
- New holders
- 11
- 6 more added
- Sold out
- 5
- 6 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BNP Paribas Arbitrage, SA | 1 | $1 | 0.00% | +1 | New |
| Salem Investment Counselors Inc | 40 | $22 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 139 | $74 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 200 | $107 | 0.00% | +200 | New |
| JPMorgan Chase & Co | 911 | $487 | 0.00% | −3−0.3% | Reduced |
| Advisor Group Holdings, Inc. | 2,355 | $1.27K | 0.00% | −15,000−86.4% | Reduced |
| Tower Research Capital LLC (TRC) | 4,008 | $2.14K | 0.00% | +3,824+2,078.3% | Added |
| Bank of America Corp | 5,625 | $3.01K | 0.00% | −375−6.3% | Reduced |
| Morgan Stanley | 11,616 | $6.22K | 0.00% | −11,833−50.5% | Reduced |
| Assenagon Asset Management S.A. | 20,785 | $11.1K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 29,552 | $16.0K | 0.00% | +29,552 | New |
| Mariner, LLC | 35,000 | $18.7K | 0.00% | −5,535−13.7% | Reduced |
| Northern Trust Corp | 40,895 | $21.9K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 41,868 | $22.4K | 0.00% | +13,766+49.0% | Added |
| XTX Topco Ltd | 44,891 | $24.0K | 0.00% | +44,891 | New |
| Millennium Management LLC | 47,025 | $25.2K | 0.00% | +47,025 | New |
| State Street Corp | 47,437 | $25.4K | 0.00% | 00.0% | Unchanged |
| Squarepoint Ops LLC | 48,971 | $26.2K | 0.00% | +48,971 | New |
| Velan Capital Investment Management LP | 50,000 | $26.8K | 0.02% | +50,000 | New |
| Goldman Sachs Group Inc | 50,020 | $26.8K | 0.00% | +50,020 | New |
| Bridgeway Capital Management, LLC | 60,200 | $32.2K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 66,113 | $35.4K | 0.00% | +30,816+87.3% | Added |
| Engineers Gate Manager LP | 72,402 | $38.7K | 0.00% | +72,402 | New |
| Citadel Advisors LLC | 78,961 | $42.3K | 0.00% | +78,961 | New |
| FMR LLC | 129,254 | $69.2K | 0.00% | +13,868+12.0% | Added |
| ADAR1 Capital Management, LLC | 244,966 | $131.1K | 0.03% | 00.0% | Unchanged |
| BlackRock, Inc. | 270,092 | $144.5K | 0.00% | +484+0.2% | Added |
| Renaissance Technologies LLC | 302,039 | $161.6K | 0.00% | +8,000+2.7% | Added |
| Geode Capital Management, LLC | 340,674 | $182.3K | 0.00% | −11,752−3.3% | Reduced |
| Pfizer Inc | 626,109 | $335.0K | 0.01% | +626,109 | New |
| Board of Trustees of The Leland Stanford Junior University | 719,546 | $385.0K | 0.03% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 1,049,153 | $561.4K | 0.08% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,067,405 | $571.1K | 0.00% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 1,166,952 | $624.4K | 0.53% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,891,467 | $1.02M | 0.69% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 2,754,437 | $1.47M | 0.11% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,521,291 | $1.88M | 0.21% | 00.0% | Unchanged |
| Tang Capital Management LLC | 3,812,773 | $2.04M | 0.13% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| Newtyn Management, LLC | 0 | $0 | 0.00% | −468,910−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −147,926−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −59,200−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −25,509−100.0% | Sold out |